Matinas BioPharma Holdings, Inc.
MTNB
$1.65
$0.042.36%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -97.53% | -35.17% | -32.05% | -5.28% |
| Gross Profit | -- | 97.53% | 35.17% | 32.05% | 5.28% |
| SG&A Expenses | -25.57% | -24.23% | -25.20% | -24.55% | -5.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.54% | -67.03% | -31.41% | -28.58% | -5.20% |
| Operating Income | 68.54% | 67.03% | 31.41% | 28.58% | 5.20% |
| Income Before Tax | 8.29% | 71.57% | -60.20% | 29.40% | 5.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.29% | 71.57% | -58.69% | 29.40% | 5.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.29% | 71.57% | -58.69% | 29.40% | 5.63% |
| EBIT | 68.54% | 67.03% | 31.41% | 28.58% | 5.20% |
| EBITDA | 68.26% | 66.82% | 31.82% | 28.92% | 5.18% |
| EPS Basic | 10.09% | 75.70% | -35.51% | 39.10% | 17.77% |
| Normalized Basic EPS | 67.43% | 71.38% | 34.40% | 39.10% | 17.77% |
| EPS Diluted | 10.09% | 75.70% | -35.51% | 39.10% | 17.77% |
| Normalized Diluted EPS | 67.43% | 71.38% | 34.40% | 39.10% | 17.77% |
| Average Basic Shares Outstanding | 2.01% | 17.02% | 17.11% | 15.94% | 14.77% |
| Average Diluted Shares Outstanding | 2.01% | 17.02% | 17.11% | 15.94% | 14.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |